CTMX
CytomX Therapeutics, Inc.
There isn't enough reported data to score CTMX yet.
CTMX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
CTMX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
CTMX PE Valuation
CTMX has no meaningful PE right now: it lost money over the past year.
CTMX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CTMX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
CTMX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.61 | -253% |
| Q2 2026 | -$0.61 | -209% |
| Q1 2026 | -$0.52 | -208% |
| Q4 2025 | -$0.15 | -139% |
| Q3 2025 | $0.40 | +122% |
| Q2 2025 | $0.56 | +273% |
| Q1 2025 | $0.48 | +129% |
| Q4 2024 | $0.38 | +$0.39 |
CTMX has swung to a loss: it lost $0.61 per share over the past year, after a profit the year before.
CTMX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7M | -72% |
| Q2 2026 | $1.4M | -92% |
| Q1 2026 | $10.3M | -80% |
| Q4 2025 | $663K | -98% |
| Q3 2025 | $6M | -82% |
| Q2 2025 | $18.7M | -26% |
| Q1 2025 | $50.9M | +23% |
| Q4 2024 | $38.1M | +43% |
CTMX's revenue has slid since its 2025 peak: $2M last quarter, down 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1392% | -1128 points |
| Q2 2026 | -1677% | -1670 points |
| Q1 2026 | -192% | -236 points |
| Q4 2025 | -4213% | -4259 points |
| Q3 2025 | -264% | -277 points |
| Q2 2025 | -6.9% | +27 points |
| Q1 2025 | 44% | +16 points |
| Q4 2024 | 46% | +49 points |
CTMX's operating margin was −1392% last quarter, down 1128 points from the same quarter a year ago, near the bottom of its range since 2019.
CTMX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $16.1M | +$31.5M |
| Q2 2026 | -$18.1M | -$2.3M |
| Q1 2026 | -$25.5M | -$4.4M |
| Q4 2025 | -$23.4M | -$3.5M |
| Q3 2025 | -$15.4M | +$5.3M |
| Q2 2025 | -$15.8M | +$3.9M |
| Q1 2025 | -$21.2M | +$5M |
| Q4 2024 | -$20M | +$2.2M |
CTMX has burned cash in almost every quarter: −$51M over the past year, against −$72M the year before.
CTMX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +167K shares |
| 1 year | +33% | +54.1M shares |
| 3 years | +171% | +138M shares |
| 5 years | +236% | +154M shares |
| Available history | +383% | +174M shares |
CTMX has 219M diluted shares, up 33% from a year ago.
CTMX Net Leverage
CTMX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CTMX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.8 | Neutral |
| Stochastic | 7.3 | Oversold |
CTMX's weekly RSI is 31 (neutral) and its Stochastic is 7 (oversold).
CTMX PE vs Healthcare Sector
| Metric | CTMX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTMX has no meaningful PE right now: it lost money over the past year.
CTMX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.38 | 14% below |
| 20 week MA | $2.98 | 32% below |
| 50 week MA | $3.82 | 47% below |
| 100 week MA | $2.87 | 29% below |
| 200 week MA | $2.23 | 8.5% below |
CTMX is in a downtrend: it's below all five of its weekly moving averages, and 8.5% below its 200-week average.
CTMX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.54 | $7.42 | -13% |
| 2021 | $7.42 | $4.22 | -43% |
| 2022 | $4.22 | $1.55 | -63% |
| 2023 | $1.55 | $1.55 | 0% |
| 2024 | $1.55 | $1.07 | -31% |
| 2025 | $1.07 | $4.39 | +310% |
| 2026 YTD | $4.39 | $2.04 | -54% |
CTMX's yearly returns have swung widely, from +310% in 2025 to −63% in 2022. It's down 54% so far in 2026.